


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE CITATION</b>	DOCKET NO. PhoenixPharFull	SERIAL NO.
	APPLICANT (S) Jaw-Kang Chang	
	FILING DATE March 30, 2001	ART UNIT

1997 U.S. PTO  
 09/822540  
  
 03/30/01

### I. U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,854,205	12-29-98	O'Reilly, et al	514	2	10-22-96

### II. FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	W09110424A1	7-25-91		A61K009	22		
	W09316716A1	09-2-93		A61K037	02		
	W09525543A1	09-28-95		A61K039	395		
	W09529242A1	11-2-95		C12N015	57		

### III. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	"Dual Drug Treatment eradicates cancer in mice", CNN, <a href="http://cnn.com/HEALTH/9805/03/cancer.mice">http://cnn.com/HEALTH/9805/03/cancer.mice</a> , May 3, 1998, pages 1-3
	"Methods for Treating Tumors Using Anti-Angiogenic Compounds", Steven K. Libutti et al, <a href="http://www.nih.gov/od/ott/0-133243.html">http://www.nih.gov/od/ott/0-133243.html</a> , May 7, 1999, page 1
	"Fighting Cancer with Angiogenesis Inhibitors", Angiogenesis Inhibitors, <a href="http://www.ultranet.com/~jkimball/BiologyPages/A/Angiogenesis.html">http://www.ultranet.com/~jkimball/BiologyPages/A/Angiogenesis.html</a> , March 31, 2000, pages 1-2
	"Angiostatin and Endostatin Scientific Abstracts", <a href="http://www.lef.org/protocols/abstracts/cancertreat-abstr.html">http://www.lef.org/protocols/abstracts/cancertreat-abstr.html</a> , March 31, 2000, pages 1-7
	"Endostatin reduces atherosclerosis in mice", <a href="http://www.biomed.lib.umn.edu/hmed/990406_end.html">http://www.biomed.lib.umn.edu/hmed/990406_end.html</a> , March 31, 2000, page 1
	"Endostatin reduced plaque developement in mice", Cardiology Today, <a href="http://www.slackinc.com/general/cardio/199908/mouse.asp">http://www.slackinc.com/general/cardio/199908/mouse.asp</a> , August 1999, pages 1-3
	"Sign-Ups begin for Trials of Tumor-Shrinking Cancer Drug", The Boston Globe, <a href="http://www.slip.net/~mcdavis/databas2/endost_5.htm">http://www.slip.net/~mcdavis/databas2/endost_5.htm</a> , September 30, 1999, pages 1-2
	"Harvard Cancer Research Questioned", The Associated Press, <a href="http://www.slip.net/~mcdavis/database/angio188.htm">http://www.slip.net/~mcdavis/database/angio188.htm</a> , November 13, 1998, pages 1-2
	"Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance", Nature, <a href="http://www.slip.net/~mcdavis/dbas9697/98049348.htm">http://www.slip.net/~mcdavis/dbas9697/98049348.htm</a> , 390(6658):404-7 1997

	"Future Anti-Angiogenic Therapy with Endostatin", Patricia Reaney, <a href="http://www.slip.net/~mcdavis/database/angio43.htm">http://www.slip.net/~mcdavis/database/angio43.htm</a> , November 26, 1997, pages 1-2
	"Drug Starves Tumors", Leslie Papp, <a href="http://www.slip.net/~mcdavis/database/endost_2.htm">http://www.slip.net/~mcdavis/database/endost_2.htm</a> , March 31, 2000, pages 1-2
	"EntreMed Inc. announces Publication of Positive Preclinical Findings Using Endostatin™ Protein Therapy in Experimental Cancer", Business Wire, <a href="http://www.slip.net/~mcdavis/database/endost/_3.htm">http://www.slip.net/~mcdavis/database/endost/_3.htm</a> , December 1, 1997, pages 1-2
	Standker, L. et al., FEBS letters 420, 1997, pp 129-133.
	Algire, G.H. et al., "Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and aneoplastic transplants", J. Natl. Canc. Inst., vol. 6, pp. 73-85 (1945).
	Chen, C. et al., "A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors", Canc Resch., vol. 55, pp. 4230-4233 (1995).
	Grant, D.S. et al., "Scatter factor induces blood vessel formation in vivo", Proc. Natl. Acad. Sci. USA, vol. 99, pp. 1937-1941 (1993).
	Muragaki, Y. et al., "Mouse col 18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones", Proc. Natl. Acad. Sci. USA, vol. 92, pp. 8763-8767 (1995).
	Studier, W.F. et al., "Use of T7 RNA polymerase to direct expression of cloned genes", Methods Enzymol., vol. 185, pp. 60-89 (1990).
	Abe et al. Blochem. Biophys Res Comm. 196:576-582, Oct. 1993.
	Oh et al. ProC. Natl. Acad. Sci. USA 91:4229-33, May 1994.
	Rehn et al. J. Biol. Chem. 269: 13929-35, May 13, 1994.
	Drug News 3:482 May 9, 1997,1990.
	Abe, N. et al., "Identification of a Novel Collagen Chain Represented by Extensive Interruptions in the Triple-Helical Region", Blochem. and Biophy. Resch. Comm., vol. 196, No. 2, pp. 576-582 (1993).
	Angiolillo, A.I. et al., "Human interferon-inducible Protein 10 is a potent inhibitor of angiogenesis in vivo", J. Exp. Med., vol. 182, pp. 155-162 (1995).
	Brem, H. et al., "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas", J. Neurosurg., vol. 74, pp. 441-446 (1991).
	Brockway, W.J. et al., "Measurement of the Binding of Antifibrinolytic Amino Acids to Various Plasminogens", Arch. Blochem. Blophys., vol. 15 1, pp. 194-199 (1972).
	Browne, M.J. et al., "Expression of Recombinant Human Plasminogen and Aglycoplasminogen in HeLa Cells", Fibrinolysis, vol. 5, pp. 257-260 (1991).
	Cao, Y. et al., "gro-beta, alpha. -C-X-C-Chemokine, Is an Angiogenesis Inhibitor That Suppresses the Growth of Lewis Lung Carcinoma in Mice", J. Exp. Med., vol. 182, pp. 2069-2077 (1995).
	Clapp, C. et al., "The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis", Endocrinology, vol. 133, pp. 1292-1299 (1993).
	Cleary, S. Mulkerrin et al., "Purification and Characterization of Tissue Plasminogen Activator Kringle-sup.2 Domain Expressed in Escherichia coli", Biochem., vol. 28, pp. 1884-1891 (1989).
	Dameron, K.M. et al., "Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-I", Science, vol. 265, pp. 1585-1584 (1994).

	Folkman, J., "Tumor angiogenesis and tissue factor", Nature Med. vol. 2, pp. 167-168 (1996).
	Folkman, J., "What is the Evidence that Tumors are Angiogenesis Dependent?", J. Natl Cane Inst., vol. 82, pp. 4-6 (1990).
	Folkman, J., "Angiogenesis in cancer, vascular, rheumatoid and other disease", Nature Medicine, vol. 1, No. 1, pp. 27-31 (1995).
	Folkman, J., "Long-term culture of capillary endothelial cells", Proc. Natl. Acad. Sci. USA 76, pp. 5217-5221 (1979).
	Folkman, J., et al., "Induction of angiogenesis during the transition from hyperplasia to neoplasia", Nature, vol. 339, pp. 58-61 (1989).
	Folkman, J. et al., "Tumor Behavior in Isolated Perfused Organs In Vitro Growth and Metastases of Biopsy Material in Rabbit Thyroid and Canine Intestinal Segment", Annals of Surgery, vol. 164, No. 3, pp. 491-501 (1996).
	Folkman, J., "Angiogenesis and Its Inhibitors", Important Advances in Oncology, J.B. Lippincott Company, pp. 42-62 (1985).
	Folkman, J., "Tumor Angiogenesis Therapeutic Implications", NE J. of Med., No. 18, pp. 1182-1186 (1971).
	Gavriell, Y. et al., "Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation", J. Cell Biol., vol. 119, pp. 493-501 (1992).
	Gimbrone, M.A. et al., "Tumor Growth and Neovascularization An Experimental Model using the Rabbit Cornea", J. Natl. Canc. Inst., vol. 52, No. 2 pp. 413-427 (1974).
	Gimbrone, M.A. et al., "Tumor Dormancy in Vivo by Prevention of Neovascularization", J. of Experi. Med., vol. 136, pp. 261-276 (1972).
	Good, D.J. et al., "A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin", Proc. Nat. Acad. Sci. USA, vol. 87, pp. 6624-6628 (1990).
	Grant, D.S. et al., "Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro", Cell, vol. 58, pp. 933-943 (1989).
	Gross, J.L. et al., "Modulation of Solid Tumor Growth in vivo by bFGF", Proc. Amer. Assoc. Canc. Resh, vol. 31, p. 79 (1990).
	Gross, J.L. et al., "Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro.", Proc. Natl. Acad. Sci. USA, vol. 80, pp. 2623-2627 (1983)
	Gunzler, W.A. et al., "The Primary Structure of High Molecular Mass Urokinase from Human Urine", Hoppe-Seyler's Z. Physiol. Chem., vol. 363, pp. 1155-1165 (1982).
	Gupta, S.K. et al., "A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4", Proc. Natl. Acad. Sci. USA, vol. 92, pp. 7779-7803 (1995).
	Holmgren, L. et al., "Dormancy of micrometastases Balanced proliferation and apoptosis in the presence of angiogenesis suppression", Nature Medicine, vol. 1, No. 2, pp. 149-153 (1995).
	Homandberg, G.A. et al., "Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth", Am. J. Path., vol. 120, pp. 327-332 (1985).

	Hori, A. et al., "Suppression of Solid tumor Growth by Immunoneutralizing Monoclonal Antibody against Human Basic Fibroblast Growth Factor", <i>Canc. Resch.</i> , vol. 51, pp. 6180-6184 (1991).
	Ingber, D. et al., "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth", <i>Nature</i> , vol. 348, pp. 555-557 (1990).
	Johansson, J. et al., "Surfactant Protein B: Disulfide Bridges, Structural Properties, and Kringle Similarities", <i>Biochem.</i> , vol. 30, pp. 6917-6921 (1991).
	Kandel, J. et al., "Neovascularization is Associated with a Switch to the Export of bFGF in the Multistep Development of Fibrosarcoma", <i>Cell</i> , vol. 66, pp. 1095-1104 (1991).
	Kim, K.J. et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo", <i>Nature</i> , vol. 362, pp. 841-844 (1993).
	Kiviniikko, S. et al., "Primary Structure of the $\alpha$ 1 Chain of Human Type XV Collagen and Exon-Intron Organization in the 3' Region of the Corresponding Gene", <i>J. Bio. Chem.</i> , vol. 269, No. 7, pp. 4773-4779 (1994).
	Knighton, D. et al., "Avascular and Vascular Phases of Tumor Growth in the Chick Embryo", <i>Br. J. Cancer</i> , vol. 35, pp. 347-356 (1977).
	Lein, W. M. et al., "The blood supply of experimental liver metastases. II. A Microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber", <i>Surgery</i> , vol. 68, No. 2, pp. 334-340 (1970).
	Lein, W. M. et al., "The blood supply of experimental liver metastases. II. A Microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber", <i>Surgery</i> , vol. 68, No. 2, pp. 334-340 (1970).
	Lerch et al., "Localization of Individual Lysine-Binding Regions in Human Plasminogen and Investigations on Their Complex-Forming Properties", <i>European Journal of Biochemistry</i> , vol. 107, No. 1, pp. 7-13 (1980).
	Lokker, N.A. et al., "Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-met receptor", <i>Prot. Engin.</i> , vol. 7, pp. 895-903 (1994).
	Marti, D. et al., "Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for $\omega$ -aminocarboxylic acids", <i>Eur. J. Biochem.</i> , vol. 219, pp. 455-462 (1994).
	McLean, J.W. et al., "cDNA sequence of human apolipoprotein(a) is homologous to plasminogen", <i>Nature</i> , vol. 330, pp. 132-137 (1987).
	Menhart, N. et al., "Construction, Expression, and Purification of Recombinant Kringle I of Human Plasminogen and Analysis of Its Interaction with $\omega$ -Amino Acids", <i>Biochem.</i> , vol. 30, pp. 1948-1957 (1991).
	Millauer, B. et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant", <i>Nature</i> , vol. 367, pp. 576-579 (1994).
	Moses, M.A. et al., "Identification of an Inhibitor of Neovascularization from Cartilage", <i>Science</i> , vol. 248 (1990).
	Nelson, J.A. et al., "Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF-and Laminin-dependent endothelial cell motility and angiogenesis", <i>Canc. Resch.</i> , vol. 55, pp. 3772-3776 (1995).
	Nguyen, M. et al., "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane", <i>Microvascular Research</i> , vol. 47, pp. 31-49 (1994).

	Nguyen, M. et al., "Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients", J. of Nat. Canc. Inst., vol. 85, No. 3, pp. 241-242 (1993).
	O'Reilly et al., "Endogenous Inhibitors of Angiogenesis", Proc. Am. Assoc. Canc. Resch., vol. 37, p. 669 (1996).
	O'Reilly et al., "Angiostatin induces and sustains dormancy of human primary tumors in mice", Nature Medicine, vol. 2, No. 6, pp. 689-692 (1996).
	O'Reilly et al., "The suppression of Tumor Metastases by a Primary Tumor", Surgical Forum, vol. XLIV, pp. 474-476 (1993).
	O'Reilly et al., "Angiostatin A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", Cell, vol. 79, pp. 315-328 (1994).
	O'Reilly et al., "Angiostatin: A Circulating Endothelial Cell Inhibitor That Suppresses Angiogenesis and Tumor Growth", Cold Spring Harbor Symposia on Quantitative Biology, vol. LIX, pp. 471-482 (1994).
	Obeso, J. et al., "Methods in Laboratory Investigation/A Hemangioendothelioma-Derived Cell Line Its Use as a Model for the Study of Endothelial Cell Biology", Laboratory Investigation, vol. 63, No. 2, p. 159 (1990).
	Oh, S.K. et al., "Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins", Proc. Natl. Acad. Sci. USA, vol. 91, pp. 4229-4233 (1994).
	Oh, S.P., "Cloning of cDNA and Genomic DNA Encoding Human Type VIII Collagen and Localization of the alpha. 1 (XVIII) Collagen Gene to Mouse Chromosome 10 and Human Chromosome 21", Genomics, vol. 19, pp. 494-499 (1994).
	Parangi, S. et al., "Antiangiogenic therapy of transgenic mice impairs de novo tumor growth", Proc. Natl. Acad. Sci. USA, vol. 93, pp. 2002-2007 (1996).
	Passaniti, A. et al., "Methods in Laboratory Investigation/A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor", Lab. Invest., vol. 67, No. 4, pp. 519-528 (1992).
	Ponting et al., "Plasminogen: a structural review", Blood Coagulation and Fibrinolysis, vol. 3, pp. 605-614 (1992).
	Powell, J. R. et al., "Amino Acid Sequence Analysis of the Asparagine-288 Region of the Carbohydrate Variants of Human Plasminogen", Biochem., vol. 22, pp. 923-927 (1983).
	Rastmjad, F. et al., "Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene", Cell, vol. 56, pp. 345-355 (1989).
	Rehn, M. et al., ".alpha. 1 (XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen", Proc. Natl. Acad. Sci. USA, vol. 91, pp. 4234-4238 (1994).
	Rehn, M. et al., "Identification of three N-terminal ends of type XVII collagen chains and tissue-specific differences in the expression of the corresponding transcripts", J. Biol. Chem., vol. 270, pp. 4705-4711 (1995).
	Robbins, K.C., "The Plasminogen-Plasmin Enzyme System", Fibrinolysis, pp. 340-357 (1987).

	Sage, E.H. et al., "Inhibition of Endothelial Cell Proliferation by SPARC is Mediated through a Ca.sup.2+ -Binding EF-Hand Sequence", J. Cell. Biochem., vol. 57, pp. 127-140 (1995).
	Sakamoto, N. et al., "Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NE.sub.2 " Canc. Resch., vol. 51, pp. 903-906 (1991).
	Sambrook, J. et al., "Expression of Cloned Genes in Eschenichia coli", Molecular Cloning Second Edition, Cold Spring Harbor Laboratories Press, pp. 17.37-17.41, (1989).
	Schaller, J. et al., "Structural Aspects of the Plasminogen of Various Species", Enzyme, 40 pp. 63-69 (1988).
	Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. Biophy. Resch. Comm., vol. 178, No. 1, pp. 360-368 (1991).
	Sottrup-Jensen, L. et al., "The Primary Structure of Human Plasminogen Isolation of Two Lysine-Binding Fragments and One Mini-Plasminogen (MW, 38,000) by Elastase-Catalyzed-Specific Limited Proteolysis", Prog. in Chem. Fibrinolysis and Thrombolysis, vol. 3, pp. 191-209 (1978).
	Srivastava, A. et al., "The Prognostic Significance of Turnorascularity in Intermediate-Thickness (0.76-4.Omm Thick) Skin Melanoma", Am. J. of Path., vol. 133, No., pp. 419-424 (1988).
	Strieter, R.M. et al., Interferon. gamma. -inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Resch. Comm., vol. 210, pp. 51-57 (1995).
	Teicher, B.A. et al., "Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents", Int. J. Canc., vol. 57, pp. 1-6 (1994).
	Tolsma, S.S. et al., "Peptides derived from two separate domains of the matrix protein thrombospondin-1 have antiangiogenic activity", J. Cell Biol., vol. 122, pp. 497-511 (1993).
	Van Meir, E. et al., "Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells", Nature Genetics, vol. 8, pp. 171-176 (1994).
	Voest, E. E. et al., "Inhibition of Angiogenesis in Vivo by Interleukin 12", J. Natl. Can. Inst., vol. 87, pp. 581-586 (1995).
	Walz, D.A. et al., "Amino acid sequence of human prothrombin fragments 1 and 2", Proc. Natl. Acad. Sci., vol. 74, pp. 1969-1973 (1977).
	Weidner, N. et al., "Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma", J. Natl. Canc. Inst., vol. 84, pp. 1875-1887 (1992).
	Weidner, N. et al., "Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Carcinoma", Am. J. Path., vol. 143, No. 2, pp. 401-409 (1993).
	Weidner, N. et al., "Tumor Angiogenesis and Metastasis--Correlation in Invasive Breast Carcinoma", NE J. of Med., vol. 324, No. 1, pp. 1-8 (1991).
	Wiman, B. et al., "On the Specific Interaction Between the Lysine-Binding Sites in Plasmin and Complementary Sites In.alpha sub.2 -Antiplasmin and Fibrinogen", Blochimica et Blophysica Acta. vol. 579, pp. 142-154 (1979).
	Yoshimura, T. et al., "Cloning, Sequencing, and Expression of Human Macrophage Stimulating Protein (MSP, MST 1) Confirms MSP as a Member of the Family of Kringle Proteins and Locates the MSP Gene on Chromosome 3", Laboratory of Immunobiology, pp. 15461-15468 (1993).

	Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Miaheshwari, S., Kleinman, H. K., Reaman, G. H., and Tosato, G. (1995). Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. <i>J. Exp. Med.</i> 182, 155-162.
	Cao, Y., Chen, C., Weatherbee, J. A., Tsang, M., and Folkman, J. (1995). Gro-beta, a C-X-C chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice. <i>J. Exp. Med.</i> 182, 2069-2077.
	Chen, C., Parangi, S., Tolentino, M. J., and Folkman, J. (1995). A strategy to discover circulating angiogenesis inhibitors generated by human tumors. <i>Cancer Res.</i> 55, 4230-4233.
	Clapp, C., Martial, J. A., Guzman, R. C., Rentier-Delrue, F., and Weiner, R. I. (1993). The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. <i>Endocrinology</i> 133, 1292-1299.
	Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. <i>Science</i> 265, 1582.
	Folkman, J. (1996). Tumor angiogenesis and tissue factor. <i>Nature Med.</i> 2, 167-168.
	Folkman, J. (1989). What is the evidence that tumors are angiogenesis dependent?. <i>J. Natl. Cancer Inst.</i> 82,4-6.
	Folkman, J. (1985). Angiogenesis and its inhibitors. In <i>Important Advances in Oncology 1985</i> , V. T. DeVita, S. Hellman, and S. Rosenberg, eds. (Philadelphia: J. B. Lippincott Company), pp. 42-62
	Folkman, J., Haundenschild, C. C., and Zetter, B. R. (1979). Long-term culture of capillary endothelial cells. <i>Proc. Natl. Acad. Sci. USA</i> 76, 5217-5221.
	Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. <i>J. Cell Biol.</i> 119, 493-501.
	Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., and Bolick, N. P. (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. <i>Proc. Nat. Acad. Sci. USA.</i> 87, 6624-6628.
	Grant, D. S., Tashiro, K.-I., Sequi-Real, B., Yamada, Y., Martin, G. R., and Kleinman, H. K. (1989). Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. <i>Cell</i> 58, 933-943.
	Gross, J. L., Moscatelli, D., and Rifkin, D. B. (1983). Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. <i>Proc. Natl. Acad. Sci. USA</i> 80, 2623-2627.
	Gupta, S. K., Hassel, T., and Singh, J. P. (1995). A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. <i>Proc. Natl. Acad. Sci. USA</i> 92, 7799-7803.
	Holmgren, L., O'Reilly, M. S., and Folkman, J. (1995). Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. <i>Nature Med.</i> 1, 149-153.
	Homandberg, G. A., Williams, J. E., Grant, D. B., S., and Eisenstein, R. (1985). Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. <i>Am. J. Path.</i> 120, 327-332.
	Hori, A., Sasada, R., Matsutani, E., Naito, K., Sakura, Y., Fujita, T., and Kozai, Y. (1991). Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. <i>Cancer Res.</i> 51, 6180-6184.
	Kandel, J., Bossy-Wetzel, E., Radvany, F., Klagsburn, M., Folkman, J., and Hanahan, D. (1991). Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. <i>Cell</i> 66, 1095-1104.
	Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. <i>Nature</i> 362, 841-844.
	Malone, T. E., Gray, G. S., Petro, J., Hunt, A. J., Donner, A. L., Bauer, S. I., Carson, H. F., and Sharpe, R. J. (1990). Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. <i>Science</i> 247, 77-79.
	Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. <i>Nature</i> 367, 576-579.

	Muragaki, Y., Timmons, S., Griffith, C. M., Oh, S. P., Fadel, B., Quertermous, T., and Olsen, B.R. (1995). Mouse col 1 8a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc. Natl. Acad. Sci. USA 92, 8763-8767.
	Nelson, J., Allen, W. E., Scott, W. N., Bailie, J. R., Walker, B., and McFerran, N. V. (1995). Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF- and laminin-dependent endothelial cell motility and <i>angiogenesis</i> . Cancer Res. 55, 3772-3776.
	Nguyen, M., Shing, Y., and Folkman, J. (1994). Quantitation of <i>angiogenesis</i> and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvascular Res. 47, 31-40.
	O'Reilly, M. S., Holmgren, L., Chen, C. C., and Folkman, J. (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2, 689-692.
	O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994). Angiostatin: A novel <i>angiogenesis</i> inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
	Obeso, J., Weber, J., and Auerbach, R. (1990). A hemangioendothelioma-derived cell line: its use as a model for the study of endothelial cell biology. Lab. Invest. 63, 259-269.
	Oh, S. K., Kamagata, Y., Muragaki, Y., Timmons, S., Ooshima, A., and Olsen, B. R. (1994). Isolation and sequencing of cDNAs for proteins with multiple domains of GlyXaa-Yaa repeats identify a distinct family of collagenous proteins. Proc. Natl. Acad. Sci. USA 91, 4229-4233.
	Parangi, S., O'Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., and Hanahan, D. (1996). Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA 93, 2002-2007.
	Rastinejad, F., Polverini, P. J., and Bouck, N. P. (1989). Regulation of the activity of a new inhibitor of <i>angiogenesis</i> by a cancer suppressor gene. Cell 56, 345-355.
	Rehn, M., and Pihlajanlehti, T. (1994). $\alpha 1(\text{XVIII})$ , a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen. Proc. Natl. Acad. Sci. USA 91, 4234-4238.
	Rehn, M., and Pihlajaniemi, T. (1995). Identification of three N-terminal ends of type XVIII collagen chains and tissue-specific differences in the expression of the corresponding transcripts. J. Biol. Chem. 270, 4705-4711.
	Sage, E. H., Bassuk, J. A., Vost, J. C., Folkman, M. J., and Lane, T. F. (1995). Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca (2+)-binding EF-hand sequence. J. Cell Biochem. 57, 127-140.
	Sakamoto, N., Iwahana, M., Tanaka, N. G., and Osaka, T. (1991). Inhibition of <i>angiogenesis</i> and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH <sub>2</sub> . Cancer Res. 51, 903-906.
	Strieter, R. M., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., and Polverini, P. J. (1995). Human interferon-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of <i>angiogenesis</i> . Biochem. Biophys. Res. Comm. 210, 51-57.
	Studier, W. F., Rosenberg, A. H., Dunn, J. J., and Doolittle, J. W. (1990). Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 85, 60-89.
	Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., and Dong, H. Z. (1994). Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int. J. Cancer 57, 1-6.
	Tolsma, S. S., Volpert, O. V., Good, D. J., Frazier, W. A., Polverini, P. J., and Bouck, N. (1993).
	Moulton KS, Heller E, Kondering MA, et al. Antiangiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization. Circulation 1999;99:1726-32
	Isner JM. The broad mandate of angiogenesis. Circulation 1999;99:1726-32

EXAMINER

DATE CONSIDERED

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.